Group 1 - The core point of the news is that Zhejiang Prodebang Pharmaceutical Co., Ltd., a subsidiary of Pro Pharmaceutical (SZ000739), has received preliminary approval for an environmental impact assessment for a project to upgrade its raw material drug production line, with a total investment of 61.96 million yuan [1] - The "A-share Green Report" project aims to enhance transparency in environmental information of listed companies by monitoring their environmental performance based on authoritative regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that nine listed companies have recently exposed environmental risks [1] Group 2 - Pro Pharmaceutical's main business is in the pharmaceutical industry, accounting for 99.6% of its revenue, with other businesses making up 0.4% [3] - The company's market capitalization is 19.462 billion yuan, with projected revenues of 11.474 billion yuan for 2023, 12.022 billion yuan for 2024, and 7.764 billion yuan for the first three quarters of 2025 [4] - The net profit attributable to the parent company is expected to be 1.055 billion yuan for 2023, 1.031 billion yuan for 2024, and 700 million yuan for the first three quarters of 2025 [4]

精彩内容 近期，集采消息频传：江苏63个品种集采开标在即，国采1-8批接续来袭，浙江拟开展第六批集采，河南34个国采可替代、用量大、金额高的药品集采提 上日程，不乏顺铂注射剂等同为国家基药和医保甲类药品种，以及丙帕他莫注射剂等2024年在河南省公立医院终端销售额超8000万元的畅销药。国家重磅 会议释放新一轮国采信号，超140个品种满足7家及以上的企业竞争格局，齐鲁、远大、倍特等过评品种数惊人。 集采品种目录再优化，聚焦可替代、用量大、金额高 今年4月，河南省医保局发布《关于开展部分药品信息摸底工作的通知》（下文简称《通知》），拟对47个国采可替代药品进行摸底，并纳入参考监测清 单。 时隔约8个月（12月9日），《河南省牵头34种药品省际联盟采购规则要点（征求意见稿）》（下文简称《意见稿》）出炉，河南牵头拟对34个国采可替代 品种以及本省遴选的用量大、金额高药品开展新一轮带量集采（下文简称"河南省集采"）。 来源：河南省医保局 从集采品种上看，《意见稿》对比《通知》剔除了氨溴索口服液体剂、硝酸异山梨酯口服常释剂型、左西替利嗪口服液体剂、脂肪乳(C14-24)注射剂、普 拉洛芬滴眼剂、七氟烷吸入剂、卡铂注射剂、 ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

普洛药业12月23日公告，公司控股子公司浙江普洛康裕制药有限公司收到国家药监局签发的磷酸奥司他 韦干混悬剂《药品注册证书》。该产品用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年 龄人群的甲型和乙型流感预防。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-77 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局（以下简称"药监局"）签发的磷酸奥 司他韦干混悬剂《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：磷酸奥司他韦干混悬剂 4、注册分类：化学药品 3 类 5、上市许可持有人：浙江普洛康裕制药有限公司 6、生产企业：浙江普洛康裕制药有限公司 7、证书编号：2025S03789 8、药品批准文号：国药准字 H20256273 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 磷酸奥司他韦的活性代谢产物（奥司他韦羧酸盐）是选择性的流感病毒神 经氨酸酶抑制剂，能够抑制甲型和乙型流感病毒的神经氨酸酶活性，通过抑制 病毒从被感染的细胞中释放，减少甲型或乙型流感病毒的播散。 磷酸奥司 ...

普洛药业（000739）(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国 家药品监督管理局签发的磷酸奥司他韦干混悬剂《药品注册证书》。 磷酸奥司他韦的活性代谢产物(奥司他韦羧酸盐)是选择性的流感病毒神经氨酸酶抑制剂，能够抑制甲型 和乙型流感病毒的神经氨酸酶活性，通过抑制病毒从被感染的细胞中释放，减少甲型或乙型流感病毒的 播散。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年龄人群的 甲型和乙型流感预防。 ...

磷酸奥司他韦的活性代谢产物(奥司他韦羧酸盐)是选择性的流感病毒神经氨酸酶抑制剂，能够抑制甲型 和乙型流感病毒的神经氨酸酶活性，通过抑制病毒从被感染的细胞中释放，减少甲型或乙型流感病毒的 播散。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年龄人群的 甲型和乙型流感预防。 智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收 到国家药品监督管理局签发的磷酸奥司他韦干混悬剂《药品注册证书》。 ...

Group 1 - Pro Pharmaceutical has obtained a food production license for bat moth mycelium powder, categorized as a health food [1] - Zhongqi Co., Ltd. has had its application for issuing convertible bonds accepted by the Shenzhen Stock Exchange [2] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind for facial dermal injections in China [3] Group 2 - Sinopharm Modern's subsidiary has received a drug registration certificate for Bumetanide injection, used for edema, hypertension, and preventing acute kidney failure [4] - Landun Optoelectronics has terminated the purchase of a stake in Star Si Semiconductor, with no payment made for the equity transfer [5] - Zhaoxin Co., Ltd. plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, positioning it as a controlling subsidiary [6] Group 3 - Chongqing Rural Commercial Bank has had the qualifications of three non-executive directors approved, effective immediately [7] - Changshan Pharmaceutical has received a drug registration certificate for Heparin Sodium injection in Turkmenistan, used for anticoagulation [8] - Changshan Pharmaceutical's vice president has resigned for personal reasons but will continue to hold other positions within the company [9] Group 4 - Shaanxi Construction has won five major projects with a total bid amount exceeding 3.912 billion yuan, covering various sectors [10][11] - Huazhong Co., Ltd. reported a 1.6% month-on-month increase in pig sales revenue for November, with a total of 34.4 million yuan [12] - Yipin Hong's subsidiary has received a drug registration certificate for Levofloxacin oral solution, effective for treating various bacterial infections [13] Group 5 - Yabo Co., Ltd.'s subsidiary has won projects totaling 7.2933 million yuan, representing 2.13% of the company's audited revenue for 2024 [14] - Sunshine Nuohe plans to invest 20 million yuan in Biling Bio, acquiring a 2.0435% stake in the company focused on nanomedicine [15] - Jinzhi Technology has won projects totaling 76.172 million yuan, accounting for 4.3% of the company's projected revenue for 2024 [16]

Core Viewpoint - Prolo Pharmaceutical Co., Ltd. has received a food production license for bat moth mycelium powder, indicating its capability to produce related food products and additives, which will help meet market demand and expand its health food business [1] Group 1 - The company’s wholly-owned subsidiary, Zhejiang Prolo Biotechnology Co., Ltd., obtained the food production license from the Zhejiang Provincial Market Supervision Administration [1] - The acquisition of the food production license signifies the company's qualification for producing specific varieties, enhancing its operational capabilities in food and food additive production [1] - The company has established a sustainable health food production capacity through advanced synthetic biology technology, covering the entire process from process design to large-scale fermentation production [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-76 普洛药业股份有限公司 关于取得食品生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛生 物科技有限公司收到浙江省市场监督管理局颁发的蝙蝠蛾被毛孢菌丝体粉的《食 品生产许可证》。现将有关情况公告如下： 三、对公司的影响 公司本次取得《食品生产许可证》，标志着公司具备了相关品种的生产资质， 有助于开展相关食品以及食品添加剂生产经营活动，更好地满足市场需求；也标 志着公司依托先进的合成生物学技术平台，实现了从工艺路线设计、高效生物合 成到规模化发酵生产的全流程、可持续的保健食品生产能力，对公司未来拓展保 健食品领域业务具有积极意义。 四、风险提示 公司一直高度重视产品研发，并非常注重产品研发、制造及销售等环节的质 1、生产者名称：浙江普洛生物科技有限公司 2、法定代表人：金毅强 3、生产地址：浙江省金华市东阳市歌山镇 4、食品类别：保健食品 量、安全和合规。但是产品的生产和销售可能会受到政策法规、市场环境变化等 不确定 ...